Nu Skin Enterprises, Inc. (NUS) EPS Estimated At $0.96

October 14, 2018 - By Ash

Nu Skin Enterprises, Inc. (NYSE:NUS) LogoInvestors sentiment increased to 1.63 in Q2 2018. Its up 0.21, from 1.42 in 2018Q1. It improved, as 28 investors sold Nu Skin Enterprises, Inc. shares while 62 reduced holdings. 43 funds opened positions while 104 raised stakes. 39.98 million shares or 1.62% more from 39.34 million shares in 2018Q1 were reported.
Lpl Lc holds 19,966 shares. Renaissance Limited Liability Corporation reported 538,800 shares. New Mexico Educational Retirement Board owns 0.04% invested in Nu Skin Enterprises, Inc. (NYSE:NUS) for 13,000 shares. New York State Teachers Retirement Sys holds 20,000 shares or 0% of its portfolio. Invesco Limited holds 0% in Nu Skin Enterprises, Inc. (NYSE:NUS) or 130,446 shares. Arrowstreet Capital Limited Partnership owns 242,995 shares for 0.05% of their portfolio. Strs Ohio reported 0% of its portfolio in Nu Skin Enterprises, Inc. (NYSE:NUS). Cibc World Markets Incorporated holds 0% or 12,717 shares in its portfolio. Fifth Third Natl Bank holds 0% of its portfolio in Nu Skin Enterprises, Inc. (NYSE:NUS) for 90 shares. Lombard Odier Asset Mgmt (Switzerland) Sa reported 12,700 shares. Natixis invested in 0% or 3,920 shares. Bank & Trust Of America Corporation De owns 81,934 shares. Landscape Capital Llc, a New Jersey-based fund reported 84,845 shares. Moreover, Eagle Boston Inv has 0.93% invested in Nu Skin Enterprises, Inc. (NYSE:NUS) for 129,368 shares. Ww Asset Mngmt has invested 0.01% in Nu Skin Enterprises, Inc. (NYSE:NUS).

Since May 2, 2018, it had 0 insider buys, and 6 sales for $2.56 million activity. $571,620 worth of Nu Skin Enterprises, Inc. (NYSE:NUS) was sold by OFFEN NEIL H.

Analysts expect Nu Skin Enterprises, Inc. (NYSE:NUS) to report $0.96 EPS on November, 7.They anticipate $0.20 EPS change or 26.32 % from last quarter’s $0.76 EPS. NUS’s profit would be $53.31 million giving it 17.88 P/E if the $0.96 EPS is correct. After having $1.08 EPS previously, Nu Skin Enterprises, Inc.’s analysts see -11.11 % EPS growth. The stock increased 2.52% or $1.69 during the last trading session, reaching $68.66. About 429,857 shares traded or 3.62% up from the average. Nu Skin Enterprises, Inc. (NYSE:NUS) has risen 32.28% since October 14, 2017 and is uptrending. It has outperformed by 16.66% the S&P500.

Nu Skin Enterprises, Inc. (NYSE:NUS) Ratings Coverage

Among 3 analysts covering Nu Skin Enterprises (NYSE:NUS), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Nu Skin Enterprises had 3 analyst reports since April 30, 2018 according to SRatingsIntel. Stifel Nicolaus upgraded it to “Hold” rating and $70 target in Friday, August 3 report. Citigroup maintained the stock with “Buy” rating in Monday, April 30 report.

Nu Skin Enterprises, Inc. develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. The company has market cap of $3.81 billion. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC Transformation anti-aging skin care systems; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products. It has a 26.25 P/E ratio. The firm also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, and LifePak nutritional supplements, as well as other anti-aging nutritional solutions and weight management products.

Another recent and important Nu Skin Enterprises, Inc. (NYSE:NUS) news was published by which published an article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within Ellington Residential Mortgage REIT, International …” on October 05, 2018.

Nu Skin Enterprises, Inc. (NYSE:NUS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News